Press release
Prostate Cancer Competitive Landscape Analysis 2026: Clinical Trial Trends, Novel Therapies, Regulatory Milestones, and Future Outlook | DelveInsight
Prostate Cancer Clinical Trial Analysis
The treatment paradigm for prostate cancer is witnessing rapid transformation, with more than 150 companies advancing innovative drug candidates across diverse clinical phases. Recent milestones include multiple FDA fast-track designations, companion diagnostic approvals, and positive clinical outcomes for therapies such as NUBEQA Registered , Xtandi Trademark , and Cabometyx Registered .
Late- and mid-stage candidates including Janssen's Niraparib (Phase III), Zenith Epigenetics' ZEN-3694 (Phase II), Seagen's Ladiratuzumab Vedotin (Phase II), Fortis Therapeutics' FOR46 (Phase I/II), and Regeneron's REGN5678 (Phase I/II)-highlight a broad range of mechanisms, spanning PARP inhibition, antibody-drug conjugates (ADCs), and bispecific antibodies. Collectively, these advancements reflect strong investment and scientific innovation aimed at enhancing survival outcomes and quality of life for prostate cancer patients.
DelveInsight's "Prostate Cancer Pipeline Insight 2026" provides a comprehensive evaluation of the global pipeline landscape, analyzing therapies across clinical stages and profiling the strategies of leading pharmaceutical innovators. According to DelveInsight, more than 150 major companies are developing over 160 therapeutic candidates in prostate cancer. The report delivers detailed insights into ongoing clinical trials, mechanisms of action, routes of administration, regulatory developments, and future commercial potential within this rapidly evolving market.
Get your free sample of the Prostate Cancer Pipeline Report today and gain strategic insights to identify opportunities, assess competitors, and strengthen your pipeline decisions @ [https://www.delveinsight.com/report-store/prostate-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]
Key Highlights from the Prostate Cancer Pipeline Report
* The prostate cancer pipeline demonstrates remarkable depth, with 150+ active companies collectively advancing 160+ drug candidates.
* Major industry participants include Merck & Co., Inc., Telix Pharmaceuticals Limited, Exelixis, Inc., AstraZeneca PLC, Pfizer Inc., Bristol-Myers Squibb Company, AbbVie Inc., BeiGene, Ltd., and Ipsen S.A., among many others-are actively developing next-generation therapies to reshape the treatment landscape.
* Prominent pipeline therapies under clinical evaluation include 177Lu-PSMA-I&T, Opevesostat (MK-5684), Cabozantinib, Capivasertib, Masitinib, Fuzuloparib, Mevrometostat (PF-06821497), ZEN-3694, OPDIVO (nivolumab), KEYTRUDA, Saruparib (AZD5305), CAN-2409, and numerous additional investigational candidates spanning radioligands, targeted inhibitors, immunotherapies, and combination regimens.
Recent Regulatory & Clinical Developments
* August 2025: Halda Therapeutics received FDA Fast Track designation for HLD-0915 for metastatic castration-resistant prostate cancer (mCRPC).
* July 2025: Trethera Corporation secured FDA Fast Track designation for TRE-515, currently in Phase I trials, including combination strategies with PSMA-targeted radioligand therapy.
* July 2025: AB Science S.A. announced FDA and EMA authorization of a confirmatory Phase III trial of masitinib in mCRPC.
* June 2025: Bayer AG, in collaboration with Orion, received FDA approval for darolutamide plus ADT for metastatic castration-sensitive prostate cancer (mCSPC), supported by strong Phase III data from the ARANOTE study.
* May 2025: Candel Therapeutics, Inc. obtained FDA RMAT designation for CAN-2409 for localized intermediate-to-high-risk prostate cancer.
* March 2025: Telix Pharmaceuticals Limited gained FDA approval for TLX007-CDx (Gozellix), a diagnostic imaging agent.
* February 2025: Ibex Medical Analytics received FDA 510(k) clearance for Ibex Prostate Detect, an AI-based diagnostic solution.
* January 2025: Clarity Pharmaceuticals secured FDA Fast Track designation for 64Cu-SAR-bisPSMA, a PET imaging agent for detecting PSMA-positive recurrence.
Additional updates across 2024-2025 include fast-track designations, investigational new drug clearances, and pivotal trial advancements for multiple targeted and radiopharmaceutical therapies.
With 150+ players and 160+ pipeline drugs, the prostate cancer space is evolving rapidly. Get your copy of DelveInsight's Prostate Cancer Pipeline Report to stay competitive @ [https://www.delveinsight.com/sample-request/prostate-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]
Prostate Cancer Overview
Prostate cancer remains one of the most prevalent malignancies among men, particularly those over 50. The disease originates in the prostate gland. While many cases progress slowly, aggressive forms can metastasize to bones and other organs, underscoring the importance of early detection.
Major risk factors include aging, genetic predisposition, family history, and lifestyle influences. Diagnosis typically involves PSA testing, digital rectal examination (DRE), MRI imaging, and biopsy confirmation.
Treatment approaches vary depending on disease stage and patient health status and may include active surveillance, surgery, radiation therapy, androgen deprivation therapy, chemotherapy, targeted therapies, and immunotherapies. Continued innovation in diagnostics and therapeutics is improving survival outcomes and expanding personalized care options.
A snapshot of the Pipeline Prostate Cancer Drugs mentioned in the report:
* 177Lu-PSMA-I&T: Curium
* Opevesostat (MK-5684; ODM-208): Merck/ Orion
* Mevrometostat (PF-06821497): Pfizer
* TRUQAP (capivasertib, AZD5363): AstraZeneca
* 177Lu-PNT2002: Lantheus
* 177Lu-DOTA-rosopatamab (TLX591): Telix Pharmaceuticals
* TAVT-45 (abiraterone acetate): Tavanta Therapeutics
* Saruparib (AZD5305): AstraZeneca
* CAN-2409 (aglatimagene besadenovec): Candel Therapeutics
* Fuzuloparib: Jiangsu Hengrui Pharmaceuticals
Discover key players, breakthrough therapies, regulatory updates, and late-stage clinical trials shaping the future of prostate cancer treatment. @ [https://www.delveinsight.com/report-store/prostate-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]
Spotlight on Key Pipeline Therapies
* Niraparib (ZEJULA) - Developed by Janssen in collaboration with GSK, this oral PARP inhibitor is in Phase III trials for metastatic prostate cancer.
* ZEN-3694 - From Zenith Epigenetics, this BET inhibitor is in Phase II development targeting oncogenic transcription pathways.
* Ladiratuzumab Vedotin - An ADC from Seagen Inc. targeting LIV-1, currently in Phase II trials.
* FOR46 - An ADC developed by Fortis Therapeutics targeting CD46, in Phase I/II studies.
* REGN5678 - A bispecific antibody from Regeneron Pharmaceuticals designed to activate T cells against PSMA-expressing tumor cells.
Stay ahead with therapeutic assessments across multiple molecule types and MoAs. For further information on the prostate cancer pipeline therapeutics, reach out @ [https://www.delveinsight.com/sample-request/prostate-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]
Clinical Development Landscape
DelveInsight's report categorizes prostate cancer therapies across:
* Late-stage (Phase III / Pre-registration)
* Mid-stage (Phase II)
* Early-stage (Phase I)
* Preclinical and discovery phases
* Discontinued or inactive programs
The analysis further evaluates drugs by route of administration (oral, intravenous, subcutaneous, parenteral, topical), molecule type (monoclonal antibodies, peptides, polymers, small molecules, gene therapies), and mechanisms of action including PSMA inhibitors, PARP inhibitors, EZH2 inhibitors, CYP17A1 inhibitors, and radioligand emitters.
Scope of the Prostate Cancer Pipeline Report
* Coverage: Global
* Therapeutic Assessment By Product Type: Mono, Combination, Mono/Combination
* Therapeutic Assessment By Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
* Therapeutics Assessment By Route of Administration: Oral, Intravenous, Subcutaneous, Parenteral, Topical
* Therapeutics Assessment By Molecule Type: Monoclonal antibody, Peptides, Polymer, Small molecule, Gene therapy
* Therapeutics Assessment By Mechanism of Action: PSMA inhibitors (Prostate-specific Membrane Antigen Inhibitors), CYP11A1 inhibitor, EZH2 inhibitor, Proto-oncogene protein c-akt inhibitor, PSMA-targeted therapy, Ionising radiation emitter, Steroidal inhibitor of CYP17A1, Poly(ADP-ribose) polymerase-1 inhibitor, Thymidine kinase expression stimulants, Poly(ADP-ribose) polymerase 2 inhibitors
* Key Prostate Cancer Companies: Merck & Co., Inc. (NYSE: MRK), Telix Pharmaceuticals Limited (ASX: TLX), Exelixis, Inc. (NASDAQ: EXEL), AstraZeneca PLC (NASDAQ: AZN), AB Science S.A. (EPA: AB), Lantheus Holdings, Inc. (NASDAQ: LNTH), Pfizer Inc. (NYSE: PFE), Bristol-Myers Squibb Company (NYSE: BMY), MacroGenics, Inc. (NASDAQ: MGNX), Xencor, Inc. (NASDAQ: XNCR), Merus N.V. (NASDAQ: MRUS), Arvinas, Inc. (NASDAQ: ARVN), Candel Therapeutics, Inc. (NASDAQ: CADL), Ipsen S.A. (EPA: IPN), LAVA Therapeutics N.V. (NASDAQ: LVTX), ESSA Pharma Inc. (NASDAQ: EPIX), Poseida Therapeutics, Inc. (NASDAQ: PSTX), Janux Therapeutics, Inc. (NASDAQ: JANX), AbbVie Inc. (NYSE: ABBV), Sorrento Therapeutics, Inc. (OTC: SRNEQ), Avacta Group plc (LSE: AVCT), BeiGene, Ltd. (NASDAQ: BGNE), Duality Biologics (HKEX: 6988), Curium, Modra Pharmaceuticals, Syntrix Pharmaceuticals, Zenith Epigenetics, Phosplatin Therapeutics, Laekna Therapeutics, Tavanta Therapeutics, Madison Vaccines, Taiho Pharmaceutical, Kangpu Biopharmaceuticals, Blue Earth Therapeutics, Aurigene Oncology, Sathgen Therapeutics, Full-Life Technologies, NextPoint Therapeutics, SL VAXiGEN, Nammi Therapeutics, and 858 Therapeutics, and others
* Key Prostate Cancer Pipeline Therapies: 177Lu-PSMA-I&T, Opevesostat (MK-5684), 177Lu-DOTA-rosopatamab, Cabozantinib, Capivasertib, Masitinib, FPI-2265, 177Lu-PNT2002, Mevrometostat (PF-06821497), Fuzuloparib, ModraDoc006, BMS-986218, Lorigerlimab, SX-682, ZEN-3694, Vudalimab, OPDIVO (nivolumab), Zenocutuzumab, Vobramitamab Duocarmazine, PT-112, LAE201, TAVT-45, pTVG-HP (MVI-816), TAS-115, KPG-121, ARV-766, CAN-2409, Saruparib (AZD5305), 177Lu-rhPSMA-10.1, Tazemetostat (Tazverik), KEYTRUDA, LAVA-1207, Masofaniten (EPI-7386), P PSMA 101, JANX 007, AUR107, MSP008-22, 225Ac-FL-020, NPX267, ABBV-969, SL-T10, Abivertinib, ETX-19477, AVA 6000, QXL138AM, BG-68501, DB-1311, and others
Explore the latest prostate cancer pipeline therapies - from PARP inhibitors to next-gen ADCs and bispecifics. Get competitive insights on Janssen, GSK, Seagen, Fortis & Regeneron. @ [https://www.delveinsight.com/sample-request/prostate-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]
Table of Contents
1. Prostate Cancer Pipeline Report Introduction
2. Prostate Cancer Pipeline Report Executive Summary
3. Prostate Cancer Pipeline: Overview
4. Analytical Perspective In-depth Commercial Assessment
5. Prostate Cancer Clinical Trial Therapeutics
6. Prostate Cancer Pipeline: Late-Stage Products (Pre-registration)
7. Prostate Cancer Pipeline: Late-Stage Products (Phase III)
8. Prostate Cancer Pipeline: Mid-Stage Products (Phase II)
9. Prostate Cancer Pipeline: Early-Stage Products (Phase I)
10. Prostate Cancer Pipeline Therapeutics Assessment
11. Inactive Products in the Prostate Cancer Pipeline
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Key Prostate Cancer Companies
14. Key Products in the Prostate Cancer Pipeline15. Prostate Cancer Unmet Needs
16. Prostate Cancer Market Drivers and Barriers
17. Future Perspectives and Conclusion
18. Analyst Views
19. Appendix
About DelveInsight
DelveInsight is a leading Healthcare Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=prostate-cancer-competitive-landscape-analysis-2026-clinical-trial-trends-novel-therapies-regulatory-milestones-and-future-outlook-delveinsight]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Prostate Cancer Competitive Landscape Analysis 2026: Clinical Trial Trends, Novel Therapies, Regulatory Milestones, and Future Outlook | DelveInsight here
News-ID: 4405445 • Views: …
More Releases from ABNewswire
Electrosurgical Devices Market to Reach USD 10,220.04 Million by 2034, Growing a …
Electrosurgical Devices Companies in the market include B. Braun Melsungen AG, ConMed Corporation, Olympus Corporation, Apyx Medical Corporation, Medtronic, Johnson & Johnson, Smith & Nephew Plc, Erbe Elektromedizin GmbH, KLS Martin Group, BOWA-electronic GmbH & Co. KG, Modern Medical, Kirwan Surgical Products, LLC, Utah Medical Products, Inc., Hangzhou AGS MedTech Co., Ltd., New Deantronics Taiwan Ltd., Parkell, Inc., Surgical Holdings, CIMPAX, Boston Scientific Corporation, and Others
The global electrosurgical devices market…
Hypertension Treatment Pipeline Shows Strong Momentum as 80+ Pharma Companies in …
DelveInsight's, "Hypertension Pipeline Insight, 2026" report provides comprehensive insights about 80+ companies and 100+ pipeline drugs in Hypertension pipeline landscape. It covers the Hypertension pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Hypertension pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore the comprehensive insights by DelveInsight and stay ahead in…
HER2-Negative Breast Cancer Clinical Trial Pipeline Expands as 70+ Companies Dri …
DelveInsight's "HER2-Negative Breast Cancer Pipeline Insight 2026" report provides comprehensive insights about 70+ companies and 75+ pipeline drugs in HER2-Negative Breast Cancer pipeline landscape. It covers the HER2-Negative Breast Cancer pipeline drug profiles, including clinical and nonclinical stage products. It also covers the HER2-Negative Breast Cancer therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Download DelveInsight's comprehensive…
Hepatocellular Carcinoma Clinical Trial Pipeline Shows Potential with Active Con …
DelveInsight's "Hepatocellular Carcinoma Pipeline Insight 2026 report provides comprehensive insights about 90+ companies and 95+ pipeline drugs in the Hepatocellular Carcinoma pipeline landscape. It covers the Hepatocellular Carcinoma pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Hepatocellular Carcinoma therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore the comprehensive insights by DelveInsight…
More Releases for Prostate
The 3D Urology and Prostate Clinics Introduces Innovative Natural and Targeted P …
The 3D Urology and Prostate Clinics introduces its innovative 3D targeted injection therapies, offering effective, natural solutions for various prostate conditions including prostatitis, enlarged prostate, and prostate cancer.
Renowned for its pioneering approach to prostate health, The 3D Urology and Prostate Clinics is bringing renewed hope to patients worldwide suffering from various prostate diseases. Utilizing advanced diagnostic techniques and a unique targeted injection method, the clinics offer specialized treatments that focus…
The 3D Urology and Prostate Clinics Introduces Advanced 3D Prostate Targeted Tre …
The 3D Urology and Prostate Clinics announces its latest breakthrough in targeted prostate treatment, offering a revolutionary approach to prostate cancer and other prostate-related conditions.
The 3D Urology and Prostate Clinics, renowned for its advanced techniques in prostate health, is proud to present its groundbreaking 3D prostate Targeted Treatment, a comprehensive and non-invasive solution for men suffering from prostate conditions. The clinic's innovative treatment is designed to target the root causes…
The 3D Urology and Prostate Clinics Unveil Innovative 3D Prostate Targeted Treat …
The 3D Urology and Prostate Clinics introduce their groundbreaking 3D prostate targeted treatment, offering a non-invasive solution for prostate health issues.
The 3D Urology and Prostate Clinics, renowned for their specialized treatments in prostate health, are proud to unveil their innovative 3D prostate targeted treatment. This cutting-edge therapy provides a non-invasive, highly effective solution for prostate-related conditions, offering patients a new path to recovery and well-being.Image: https://i.imgur.com/NCfbb6S.jpg
At the heart of this…
The 3D Urology and Prostate Clinics Unveils Advanced 3D prostate Targeted Treatm …
The 3D Urology and Prostate Clinics is at the forefront of prostate care, offering the advanced 3D Targeted Therapy as a precise and effective treatment solution.
The 3D Urology and Prostate Clinics is proud to announce its revolutionary 3D prostate Targeted Treatment [http://www.3dprostatecure.com/page.php?cata_id=19], setting a new standard in prostate care. This highly advanced treatment option utilizes cutting-edge technology to deliver focused treatment, minimizing side effects and enhancing recovery for patients. Men…
3D Prostate Cure: Revolutionizing Prostate Treatment with Targeted Therapy
This news release highlights the 3D Urology and Prostate Clinics' innovative approach to prostate treatment using 3D Targeted Therapy, offering a safe and effective alternative to traditional methods.
As a global leader in men's health, The 3D Urology and Prostate Clinics is committed to providing cutting-edge treatments for various prostate conditions. The clinic is proud to announce its revolutionary 3D Targeted Therapy, offering a new standard in prostate care.
This innovative therapy…
The 3D Urology and Prostate Clinics Enhance Prostate Health with Advanced 3D Pro …
The 3D Urology and Prostate Clinics are revolutionizing prostate care with their comprehensive treatments, including the 3D prostate Targeted Treatment and 3D Targeted Therapy, developed to ensure effective, non-surgical solutions for prostate health issues.
At the forefront of prostate health, The 3D Urology and Prostate Clinics are excited to offer innovative treatments such as the 3D prostate Targeted Treatment and 3D Targeted Therapy. These treatments are part of the clinic's commitment…
